title: Intravenous immunoglobulin in women with five or more abortions.
abstract: OBJECTIVE
  Treatment for recurrent miscarriage has usually been given to all women with three or more abortions of unknown cause. As these patients have a 50-60% subsequent live birth rate, no treatment has been shown to unequivocally improve the live birth rate. Immunoglobulin is the latest treatment to be applied. In order to determine if immunoglobulin improves the live birth rate, we analyzed the results of patients expected to have a poor outcome in the subsequent pregnancy if left untreated, i.e., women with five or more abortions, who have aborted after paternal leucocyte immunization or who continue to abort despite possessing anti-paternal complement dependent antibody (APCA).
  
  
  METHODS
  A preliminary trial was carried out using immunoglobulin (Sandoglobulin, Sandoz, Switzerland). It was infused at a dose of 400 mg/Kg body weight, in the follicular phase of a cycle in which pregnancy was planned. A booster dose was administered as soon as pregnancy was diagnosed.
  
  
  RESULTS
  Twelve patients were treated, ten conceived. Five have had subsequent live births. Two infants were premature but their size was appropriate for gestational age. The other three infants delivered at term.
  
  
  CONCLUSIONS
  This is still too small a group from which to draw definite conclusions about the efficacy of immunoglobulin to prevent abortion. However, five live births in ten patients is an encouraging result, especially when the expected poor obstetric outcome is considered. Hence the efficacy of immunoglobulin should be evaluated further in high risk patients.
authors: Dept. of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.
authors: H J
authors: HJ
authors: Carp
authors: R
authors: R
authors: Ahiron
authors: S
authors: S
authors: Mashiach
authors: Y
authors: Y
authors: Schonfeld
authors: E
authors: E
authors: Gazit
authors: V
authors: V
authors: Toder
mesh_terms: D000026:Abortion, Habitual / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D001723:Birth Rate; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011379:Prognosis
chemical_list: D016756:Immunoglobulins, Intravenous